Alvelestat

Phase 2Small molecule

UUniversity of Alabama at Birmingham

Alvelestat is one of 34 small molecule programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

Alpha-1 Antitrypsin DeficiencyActive, not recruiting

COVID-19Phase 1/Phase 2

Active, not recruiting

Alpha-1 Antitrypsin DeficiencyPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

COVID-19 Vaccine

Moderna

Preclinical

27 2

Aldactone

Pfizer

Preclinical

1 3

Nexavar

Bayer

Preclinical

1 4

Alvelestat

UUniversity of Alabama at Birmingham

Phase 2

1 5

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 6

Benadryl

PParkedale

Preclinical

1 7

SARS-COV-2 VACCINE

Moderna

Preclinical

2 8

Conventional

PPopulation Health Research Institute

Preclinical

1 9

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 10

Moderna COVID-19 Vaccine

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-191 trial

COVID-19 Study of Safety and Tolerability of Alvelestat

Completed·UUniversity of Alabama at Birmingham·Phase 1/2·NCT04539795·15 enrolled

Alpha-1 Antitrypsin Deficiency1 trial

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT03679598·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Alvelestat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alvelestat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alvelestat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Alabama at Birmingham

Alvelestat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-191 trial

Alpha-1 Antitrypsin Deficiency1 trial

References

Drug Info

Quick Facts

Related News